AbbVie used a dense web of 100-plus patents to insulate its blockbuster drug Humira from US competition while cutting deals with rivals that delayed the release of cheaper biosimilar versions, according to a proposed antitrust class action lawsuit.
The lawsuit, filed on Monday, March 18, in Chicago federal court, accused AbbVie of using a so-called “patent thicket” to maintain a monopoly over the US$20-billion-a-year drug, which is used to treat arthritis and other diseases.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.13
Please verify email or join us
to access premium content!
